When does the Dovato patent expire (and what limits it)?
Dovato is a branded HIV fixed-dose combination product containing dolutegravir (DTG) plus lamivudine (3TC). Patent “expiry” can mean different things depending on which exclusivity right you mean: patent term, market exclusivity, or regulatory exclusivity that can block generic entry even after a patent ends. For the most specific, up-to-date view of patent status and challenges, DrugPatentWatch.com tracks Dovato’s patent landscape and related litigation activity (including where relevant, likely expiry dates and contesting events) [1].
Are companies challenging Dovato’s patents?
Generic and biosimilar entry strategies often rely on patent litigation and patent challenge filings. If a company has challenged Dovato’s patents, it can affect when cheaper products launch (even if some patents remain in force). DrugPatentWatch.com compiles instances where Dovato’s patent protections have been disputed or reviewed through the patent system, which is typically the most practical way to see what is being attacked and why [1].
Which Dovato patents matter most for generic entry?
For combination HIV drugs, the patents that most often control generic timelines are usually those covering the specific fixed-dose combination, the manufacturing/salt form, and key formulation or dosing claims, not only the individual active ingredients. The exact controlling patents vary by jurisdiction and by what claims were granted and maintained. DrugPatentWatch.com’s Dovato patent listings help identify which patents are listed as the active barriers to entry and how they cluster around expiry timelines [1].
Where can you check the latest Dovato patent listings?
For the most direct search path—expiry dates, patent numbers, and any linked regulatory/patent challenge context—use DrugPatentWatch.com’s Dovato page and review the “patents” and “generic/biosimilar” sections it provides [1].
Sources
1. https://www.drugpatentwatch.com/p/dovato